默克公司、百时美施贵宝公司宣布大幅降低对最贫穷国家的药品价格：在药品可及性方面取得重大进展，但问题依然存在。
Merck, Bristol-Myers Squibb announce major price reductions for poorest countries: major access progress but questions remain.
作者信息
James J S
出版信息
AIDS Treat News. 2001 Feb 28(361):5-7.
PMID:12765151
Abstract
Two major pharmaceutical companies have announced new and much lower prices for antiretrovirals for African and some other poor countries, along with a uniform pricing policy which should simplify negotiations for access to the drugs.
摘要
两家大型制药公司宣布为非洲及其他一些贫穷国家的抗逆转录病毒药物制定新的、低得多的价格，并出台统一定价政策，这有望简化获取这些药物的谈判流程。
相似文献
1
2
Companies reduce prices for HIV drugs in developing countries.制药公司降低了在发展中国家销售的抗艾滋病药物的价格。
Bull World Health Organ. 2000;78(6):862.
3
Drug makers to cut prices for developing countries.
AIDS Alert. 1998 Aug;13(8 Suppl):1-2.
4
[HIV therapy: tenofir DF is available in 68 developing countries at production costs price].[艾滋病治疗：在68个发展中国家可按生产成本价格获得替诺福韦酯]
Med Klin (Munich). 2003 Jul 15;98(7):XV-XVI.
5
A visit to India: drug prices, research, & global access.
AIDS Treat News. 1999 Jan 22(No 311):6-8.
6
Drug prices.药品价格
AIDS Policy Law. 1996 Dec 27;11(22):12.
7
The (political) economics of antiretroviral treatment in developing countries.发展中国家抗逆转录病毒治疗的（政治）经济学
Trends Microbiol. 2008 Dec;16(12):574-9. doi: 10.1016/j.tim.2008.08.012. Epub 2008 Oct 27.
8
Essential AIDS medications in India.印度的基本艾滋病药物。
Issues Med Ethics. 2000 Apr-Jun;8(2):62.
9
Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.耐药性、专利耐药性：印度制药业与新专利制度的影响。
Glob Public Health. 2009;4(6):515-27. doi: 10.1080/17441690902796449.
10
Access to essential drugs, human rights and global justice.基本药物的可及性、人权与全球正义。
Monash Bioeth Rev. 2004 Jan;23(1):S56-74.
Zotero 插件